Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US
RSV vaccine sales by GSK and Pfizer have dropped in the U.S. after regulators limited the eligible age group, affecting ...
Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...
AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...
As of now, Pfizer’s stock has recorded a year-to-date (YTD) performance of +3.73%. In contrast, the S&P 500 has experienced a much more robust gain of +20.57%. This stark difference in performance ...
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback